Literature DB >> 27430444

Magnetic resonance imaging of skeletal muscle disease.

Bruce M Damon1, Ke Li2, Nathan D Bryant2.   

Abstract

Neuromuscular diseases often exhibit a temporally varying, spatially heterogeneous, and multifaceted pathology. The goals of this chapter are to describe and evaluate the use of quantitative magnetic resonance imaging (MRI) methods to characterize muscle pathology. The following criteria are used for this evaluation: objective measurement of continuously distributed variables; clear and well-understood relationship to the pathology of interest; sensitivity to improvement or worsening of clinical status; and the measurement properties of accuracy and precision. Two major classes of MRI methods meet all of these criteria: (1) MRI methods for measuring muscle contractile volume or cross-sectional area by combining structural MRI and quantitative fat-water MRI; and (2) an MRI method for characterizing the edema caused by inflammation, the measurement of the transverse relaxation time constant (T2). These methods are evaluated with respect to the four criteria listed above and examples from neuromuscular disorders are provided. Finally, these methods are summarized and synthesized and recommendations for additional quantitative MRI developments are made.
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MRI; atrophy; biomarker; fat infiltration; fibrosis; inflammation; inflammatory myopathy; muscle; muscular dystrophy

Mesh:

Year:  2016        PMID: 27430444     DOI: 10.1016/B978-0-444-53486-6.00041-7

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  5 in total

Review 1.  [Imaging of primary muscular diseases : What do neurologists expect from radiologists?]

Authors:  M P Wattjes; A Fischmann; D Fischer
Journal:  Radiologe       Date:  2017-12       Impact factor: 0.635

2.  A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial.

Authors: 
Journal:  Radiother Oncol       Date:  2018-09-08       Impact factor: 6.280

3.  Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials.

Authors:  Jordi Diaz-Manera; Roberto Fernandez-Torron; Jaume LLauger; Meredith K James; Anna Mayhew; Fiona E Smith; Ursula R Moore; Andrew M Blamire; Pierre G Carlier; Laura Rufibach; Plavi Mittal; Michelle Eagle; Marni Jacobs; Tim Hodgson; Dorothy Wallace; Louise Ward; Mark Smith; Roberto Stramare; Alessandro Rampado; Noriko Sato; Takeshi Tamaru; Bruce Harwick; Susana Rico Gala; Suna Turk; Eva M Coppenrath; Glenn Foster; David Bendahan; Yann Le Fur; Stanley T Fricke; Hansel Otero; Sheryl L Foster; Anthony Peduto; Anne Marie Sawyer; Heather Hilsden; Hanns Lochmuller; Ulrike Grieben; Simone Spuler; Carolina Tesi Rocha; John W Day; Kristi J Jones; Diana X Bharucha-Goebel; Emmanuelle Salort-Campana; Matthew Harms; Alan Pestronk; Sabine Krause; Olivia Schreiber-Katz; Maggie C Walter; Carmen Paradas; Jean-Yves Hogrel; Tanya Stojkovic; Shin'ichi Takeda; Madoka Mori-Yoshimura; Elena Bravver; Susan Sparks; Luca Bello; Claudio Semplicini; Elena Pegoraro; Jerry R Mendell; Kate Bushby; Volker Straub
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-05-07       Impact factor: 10.154

4.  Segmentation of the fascia lata and reproducible quantification of intermuscular adipose tissue (IMAT) of the thigh.

Authors:  Oliver Chaudry; Andreas Friedberger; Alexandra Grimm; Michael Uder; Armin Michael Nagel; Wolfgang Kemmler; Klaus Engelke
Journal:  MAGMA       Date:  2020-08-06       Impact factor: 2.310

5.  High-Resolution MR Imaging of Muscular Fat Fraction-Comparison of Three T2-Based Methods and Chemical Shift-Encoded Imaging.

Authors:  Lena Trinh; Emelie Lind; Pernilla Peterson; Jonas Svensson; Lars E Olsson; Sven Månsson
Journal:  Tomography       Date:  2017-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.